Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Glutamine
Drug ID BADD_D01029
Description A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from glutamic acid and ammonia. It is the principal carrier of nitrogen in the body and is an important energy source for many cells. An oral formulation of L-glutamine was approved by the FDA in July 2017 for use in sickle cell disease [L892]. This oral formulation is marketed under the tradename Endari by Emmaus Medical.
Indications and Usage Used to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older [FDA Label].
Marketing Status Prescription
ATC Code A16AA03
DrugBank ID DB00130
KEGG ID D00015
MeSH ID D005973
PubChem ID 5961
TTD Drug ID D01JIA
NDC Product Code 51552-0285; 58159-080
Synonyms Glutamine | L-Glutamine | L Glutamine | D-Glutamine | D Glutamine
Chemical Information
Molecular Formula C5H10N2O3
CAS Registry Number 56-85-9
SMILES C(CC(=O)N)C(C(=O)O)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ApoptosisGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available7789306; 8638660; 9060444; 12679868; 9519709; 8663078; 10997922; 9453242; 11399656
ApoptosisLatent-transforming growth factor beta-binding protein 1Q14766Not Available11163803; 12802498
ApoptosisGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available11163803; 12802498
Cytogenetic investigationsGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available7789306; 8638660; 9060444; 12679868; 9519709; 8663078; 10997922; 9453242; 11399656
Cytogenetic investigationsEpidermal growth factor receptorP00533T593287789306; 8638660; 9060444; 12679868; 9519709; 8663078; 10997922; 9453242; 11399656
Cytogenetic investigationsGlutamine--fructose-6-phosphate aminotransferase [isomerizing] 1Q06210Not Available11163803; 12802498
Gastrointestinal disordersCalnexin homolog 1P29402Not Available12624106; 15944403; 9092938
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Arthralgia15.01.02.001--
Asthenia08.01.01.001--Not Available
Back pain15.03.04.005--
Body temperature increased13.15.01.001--Not Available
Breast pain21.05.05.003--
Chest pain02.02.02.011; 22.02.08.003; 08.01.08.002--Not Available
Chills15.05.03.016; 08.01.09.001--
Constipation07.02.02.001--
Crohn's disease10.02.01.005; 07.08.01.015--Not Available
Dehydration14.05.05.001--
Depression19.15.01.001--
Dermatitis23.03.04.002--Not Available
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Dry mouth07.06.01.002--
Ear disorder04.03.01.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014--Not Available
Flatulence07.01.04.002--
Fungal infection11.03.05.001--Not Available
Gastric ulcer07.04.03.002--
Gastrointestinal fistula07.11.05.001--
Gastrointestinal pain07.01.05.005--
Generalised oedema14.05.06.007; 08.01.07.004--
Haemorrhoids07.15.03.001; 24.10.02.002--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001--Not Available
The 1th Page    1 2 3    Next   Last    Total 3 Pages